Ontology highlight
ABSTRACT:
SUBMITTER: Kholdani CA
PROVIDER: S-EPMC4251661 | biostudies-other | 2014
REPOSITORIES: biostudies-other
Vascular health and risk management 20141125
Macitentan is the most recently approved dual endothelin-receptor antagonist (ERA) for the treatment of symptomatic pulmonary arterial hypertension. Compared to other available ERAs, it demonstrates superior receptor-binding properties, with consequently improved tissue penetration, and a longer duration of action allowing for once-daily dosing. It has a favorable adverse-effect profile, with notably no demonstrable increase in the risk of hepatotoxicity or peripheral edema, but like other ERAs, ...[more]